Lung Cancer

David R. Gandara, MD, discusses the latest immunotherapy developments in lung cancer and the next steps toward optimizing the benefit of these agents.

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses PARP inhibitors for patients with non-small cell lung cancer (NSCLC).

Maximilian Diehn, MD, PhD, an assistant professor in the Department of Radiation Oncology, Stanford Medicine, discusses some of the next steps researchers are taking with liquid biopsies in the field of lung cancer.

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the MYSTIC trial for patients with non-small cell lung cancer (NSCLC)

Nintedanib, an angiogenesis inhibitor, is being investigated as a first-line treatment for patients with unresectable malignant pleural mesothelioma (MPM).

Monotherapy with a tyrosine kinase inhibitor is the frontline standard of care for patients with advanced EGFR-mutant non–small cell lung cancer, with 3 currently approved agents: erlotinib, gefitinib, and afatinib.

Lyudmila A. Bazhenova, MD, discusses the non-driver NSCLC population, the treatment strategies available for them, and challenges physicians continue to face with this subgroup of patients.

ASCO has updated its guidelines for first- and second-line treatment of patients with stage IV non–small cell lung cancer.

Monte Winslow, PhD, shares the work on CRISPR being developed in his lab, and how this technology might help advance treatment for the non-driver NSCLC population.

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses pembrolizumab (Keytruda) plus chemotherapy and radiation therapy in patients with lung cancer.

Billy W. Loo Jr, MD, PhD, discusses the advancements in radiation therapy options for patients with lung cancer, how SABR has improved outcomes for patients, and the intriguing combinations being explored with RT and immunotherapy.

Maximilian Diehn, MD, PhD, discussed the future of NGS platforms and liquid biopsies and his vision for them eventually becoming standard practice for patients with lung cancer.

Millie Das, MD, discusses the difficulties of the non-driver non-small cell lung cancer patient population, interesting clinical trials that could reshape therapeutic options, and her belief that these patients do have molecular targets that have yet to be identified.

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer.